Biostage, Inc. s in-depth stock price analysis indicates that the stock price has dropped -62.9% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -67.69% . Looking at the past 52 week period, the stock price is down -75.17% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Biostage, Inc. has a negative value of -50.28 compared to overall market performance. Biostage, Inc. (NASDAQ:BSTG) has tumbled 55.87% during the past week and has dropped 64.23% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 56.23%. Biostage, Inc. (NASDAQ:BSTG) has underperformed the index by 64.87% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Biostage, Inc. (NASDAQ:BSTG) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.2061 points or 40.68% at $0.3005 with 11,353,310 shares getting traded. Post opening the session at $0.3, the shares hit an intraday low of $0.2925 and an intraday high of $0.329 and the price was in this range throughout the day. The company has a market cap of $5.1 million and the number of outstanding shares has been calculated to be 17,108,968 shares. The 52-week high of Biostage, Inc. (NASDAQ:BSTG) is $2.8599 and the 52-week low is $0.2925.
Biostage, Inc. is a biotechnology company. It is engaged in developing bioengineered organ implants based on the companys new Cellframe (TM) technology to treat life-threatening conditions of the esophagus, trachea or bronchus. Biostage Inc., formerly known as Harvard Apparatus Regenerative Technology Inc., is based in HOLLISTON, Mass.